ZRO — Biosenta Income Statement
0.000.00%
- CA$5.04m
- CA$10.93m
- CA$0.00m
- 29
- 11
- 35
- 13
Annual income statement for Biosenta, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.002 | 0.168 | 0.001 | 0.001 | 0.001 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.099 | 0.001 | 0 | 0.001 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.763 | 2.21 | 1.46 | 6.3 | 1.19 |
Operating Profit | -0.762 | -2.04 | -1.46 | -6.3 | -1.18 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.762 | -2.04 | -1.46 | -6.3 | -2.23 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.762 | -2.04 | -1.46 | -6.3 | -2.23 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.762 | -2.04 | -1.46 | -6.3 | -2.23 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.762 | -2.04 | -1.46 | -6.3 | -2.23 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.048 | -0.114 | -0.067 | -0.058 | -0.075 |